CureVac (NASDAQ:CVAC) Sees Unusually-High Trading Volume – What’s Next?

Shares of CureVac (NASDAQ:CVAC) saw strong trading volume on Tuesday . 1,377,593 shares were traded during trading, a decline of 18% from the previous session’s volume of 1,689,576 shares.The stock last traded at $4.93 and had previously closed at $4.44.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.

CureVac Stock Performance

The stock has a market capitalization of $1.05 billion, a P/E ratio of 8.55, a price-to-earnings-growth ratio of 0.24 and a beta of 2.50. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average price of $2.96 and a two-hundred day moving average price of $3.12.

Hedge Funds Weigh In On CureVac

Several institutional investors have recently added to or reduced their stakes in CVAC. Private Advisor Group LLC bought a new stake in shares of CureVac in the 3rd quarter valued at $30,000. International Assets Investment Management LLC bought a new stake in CureVac in the third quarter valued at $35,000. Integrated Wealth Concepts LLC acquired a new position in shares of CureVac during the third quarter valued at about $35,000. Bank of New York Mellon Corp bought a new position in shares of CureVac during the 2nd quarter worth about $54,000. Finally, Barclays PLC acquired a new stake in shares of CureVac in the 3rd quarter valued at about $67,000. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.